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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
• To estimate the benefit and safety of all DMDs that have been evaluated in all studies (randomised and non-randomised) for
early treatment. We will employ novel, high-quality methods for systematic reviews and network meta-analysis in collaboration with
the Cochrane Multiple Interventions Group.
• To evaluate the quality of the evidence provided by existing studies. We will consider the credibility of included studies and other
characteristics of the evidence base as we characterise conclusions pertaining to high, low or very low quality of evidence.
We will undertake this review in accordance with the methods described by the template protocol published online and will use this
template as we prepare the review.
B A C K G R O U N D
Description of the condition
With the introduction of the 2001 McDonald criteria and their
2005 and 2010 revisions, multiple sclerosis (MS) could be diag-
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nosed at the time of a first clinical attack with magnetic resonance
imaging (MRI) of the brain and the whole spine (McDonald 2001;
Polman 2005; Polman 2011).Opinion leaders have recommended
early action as follows: “treating at first clinical attack may be the
most effective strategy to manage disease progression” (Freedman
2014). Revised guidelines of the Association of British Neurolo-
gists (Scolding 2015) and NHS England (NHS England 2014)
suggest that treatment should be advised for patients within 12
months of a first attack, if MRI establishes a diagnosis of MS ac-
cording to 2010 McDonald criteria or predicts a high likelihood
of recurrent attacks.
Once the decision is made for early treatment, patients and their
healthcare providers need to select one of several disease-modifying
drugs (DMDs). The benefit of starting early treatment withDMD
has been demonstrated by some short-term trials that showed de-
lay of recurrent attacks or fewer lesions in participants given in-
terferons beta or glatiramer acetate compared with those given
placebo (Comi 2001; Comi 2012). On the basis of these results,
interferons beta and glatiramer acetate were approved by national
regulatory agencies for treatment of a first attack (EMA 2015a).
Guidelines of the Association of British Neurologists indicate that
alemtuzumab and natalizumab are more efficient in preventing
relapses. However, because of safety concerns, these guidelines rec-
ommend that these agents be given as second-line treatment, or
as treatment for patients with rapidly evolving relapsing-remitting
MS (RRMS); beta interferons, glatiramer acetate, teriflunomide,
dimethyl fumarate and fingolimod are recommended as first-line
agents (the first therapy) (Scolding 2015). On the contrary, Aus-
tralian and New Zealand guidelines suggest that all DMDs can be
used as first-line treatment if the attending neurologist so judges
(Broadley 2014).
No definitive evidence suggests that delayed recurrent clinical at-
tacks or fewer MRI lesions over the two-year period reported in
randomised trials translate into medium- or long-term benefit
(Frischer 2009; Kinkel 2012), and large variability of long-term
disability worsening has been reported even among people with
frequent early relapses (Scalfari 2013).
We published a Cochrane review on benefit and acceptability of
DMDs in people with RRMS. Evidence of moderate to high qual-
ity suggests that alemtuzumab, natalizumab and fingolimod when
compared with placebo were associated with greater benefit for
preventing clinical relapse, and evidence of moderate quality in-
dicates that natalizumab was associated with greater benefit than
placebo for preventing worsening of disability among all treat-
ments evaluated (Tramacere 2015).
Description of the intervention
Wewill consider all DMDs that are used, approved or off-label, or
are currently under marketing authorisation or investigation for
people with a first clinical attack of MS. We will consider that all
agents used or under investigation for RRMS could be given to
people with a first attack complying with 2010McDonald criteria.
• Approved for a first attack complying with 2010 McDonald
criteria.
◦ Beta interferons (Betaferon/Betaseron®; Extavia®;
Rebif®; Avonex®) and glatiramer acetate (Copaxone®) (EMA
2015a; FDA 2012a; FDA 2012b; FDA 2013). These
medications are administered subcutaneously, except for beta
interferon 1a (Avonex®), which is administered via
intramuscular injections.
• Approved for RRMS.
◦ Natalizumab (Tysabri®) (EMA 2006; FDA 2006),
administered by intravenous infusion at a dose of 300 mg every
four weeks.
◦ Fingolimod (Gilenya®) (EMA 2011; FDA 2010),
given at an oral dose of 0.5 mg once daily.
◦ Teriflunomide (Aubagio®) (EMA 2013a; FDA 2012),
given at an oral dose of 7 or 14 mg once daily.
◦ Dimethyl fumarate (Tecfidera®) (EMA 2014a; FDA
2013), given at an oral dose of 240 mg twice daily.
◦ Alemtuzumab (Lemtrada®) (EMA 2013b; FDA
2014a), administered intravenously in two annual treatment
courses - the first at a dose of 12 mg daily on five consecutive
days (60 mg total dose), and the second, 12 months later, on
three consecutive days (36 mg total dose).
◦ Daclizumab (Zinbryta®), administered by
subcutaneous or intravenous injections and approved by the
European Medicines Agency (EMA) (EMA 2016). The review
process of the Food and Drug Administration(FDA) (Biogen
2015b) is ongoing.
◦ Peginterferon beta-1a (Plegridy®) (EMA 2014b; FDA
2014b), given by subcutaneous injection at a dose of 125
micrograms every 14 days.
◦ Cladribine (Movectro®), approved in Russia and
Australia in 2010 (Murphy 2010) but refused by the EMA
(EMA 2015b) and the FDA in 2011 because of a suspected
increase in cancer risk. This has not been confirmed by results of
a meta-analysis of trials (Pakpoor 2015). Cladribine was
investigated in two trials (Giovannoni 2010; Leist 2014).
◦ Mitoxantrone (Novantrone®), approved in 2000 in
the USA (FDA 2000), Europe and other countries for RRMS
and progressive MS, administered as a short intravenous infusion
every three months. Safety issues of concern for people treated
with mitoxantrone include cardiotoxicity and acute leukaemia.
• Used off-label.
◦ Azathioprine (Imuran®), used for the treatment of MS
in many countries on the basis of placebo-controlled randomised
controlled trials (RCTs) published more than two decades ago.
However, since interferons beta were approved, azathioprine is
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no longer recommended as first-line therapy (Goodin 2002). It is
taken daily orally as a 2 or 3 mg/kg tablet.
◦ Intravenous immunoglobulins used for people with
severe and frequent relapses, for whom other treatments were
contraindicated (Scolding 2015)
◦ Rituximab (Rituxan® or Mabthera®), evaluated in one
trial (Hauser 2008). Study authors found beneficial effects on
clinical and MRI-visualised disease activity that was maintained
over 48 weeks. The drug is administered intravenously.
• Currently under marketing authorisation or investigation.
◦ Laquinimod (Nerventra®), evaluated in two trials for
RRMS at an oral dose of 0.6 mg daily (Comi 2012; Vollmer
2014). The drug received a negative opinion from the EMA
(EMA 2014c). Additional studies of laquinimod in RRMS are
ongoing (Active Biotech 2014).
◦ Ocrelizumab is under development for treatment of
patients with RRMS, and clinical trials are ongoing (Hauser
2015; Kappos 2011; Montalban 2015). It is administered by
intravenous infusion every 24 weeks.
How the intervention might work
Immunosuppressive or immunomodulatory effects are common
to all treatments included in the review.
• Approved.
◦ Beta interferons are naturally occurring cytokines that
possess antiviral activity and a wide range of anti-inflammatory
properties. Recombinant beta interferons are believed to directly
increase expression and concentration of anti-inflammatory
agents, while downregulating expression of pro-inflammatory
cytokines (Kieseier 2011).
◦ Glatiramer acetate exerts an immunomodulatory
action by inducing tolerance or anergy of myelin-reactive
lymphocytes (Schmied 2003). Glatiramer acetate may promote
neuroprotective repair processes (Aharoni 2014).
◦ Natalizumab is a humanised monoclonal antibody
directed against the alfa4 integrin. This integrin is essential in the
process by which lymphocytes gain access to the brain by
allowing cells to penetrate the blood-brain barrier. Natalizumab
binds alfa4β1 and alfa4β7 integrin on the surface of circulating
T lymphocytes, preventing interaction with cellular adhesion
molecules that facilitate extravasation and migration from the
circulation to the central nervous system (CNS) (Millard 2011).
◦ Fingolimod is a sphingosine-1-phosphate (S1P)
receptor modulator that prevents lymphocyte egress from
lymphoid tissues, thereby reducing autoaggressive lymphocyte
infiltration into the CNS. S1P receptors are also expressed by
many CNS cell types and have been shown to influence cell
proliferation, morphology and migration. Fingolimod crosses the
blood-brain barrier and therefore may have direct CNS effects
(Chun 2010).
◦ Teriflunomide acts as an inhibitor of dihydroorotate
dehydrogenase (DHODH), a mitochondrial enzyme involved in
pyrimidine synthesis for DNA replication in rapidly proliferating
cells. The drug reduces T lymphocyte and B lymphocyte
activation and proliferation, and may attenuate the
inflammatory response to autoantigens in MS. However, the
exact mechanism of action for teriflunomide is not fully
understood. Some observations suggest that the drug may have
immunological effects outside of its ability to inhibit pyrimidine
synthesis in rapidly proliferating cells (Claussen 2012; Oh 2013).
◦ Dimethyl fumarate derives from fumaric acid,
promotes anti-inflammatory activity and can inhibit expression
of pro-inflammatory cytokines and adhesion molecules. Actions
of neuroprotective and myelin-protective mechanisms have been
proposed (Linker 2011; Wilms 2010).
◦ Alemtuzumab is a monoclonal antibody to CD52 on
the cell surface of lymphocytes and monocytes. Its effects are
thought to be mediated by extended B and T lymphocyte
depletion followed by a distinctive pattern of T and B cell
repopulation that begins within weeks of treatment and leads to
a rebalanced immune system, including an increased percentage
of regulatory and memory T cells. Effects of alemtuzumab
persisted after it was cleared from the circulation (Lycke 2015).
◦ Daclizumab is a monoclonal antibody to the
interleukin-2 receptor CD25 that is expressed on immune cells.
The exact mechanism is not well understood. Daclizumab
interrupts interleukin-2-mediated cell activation, thereby
preventing expansion of autoreactive T lymphocytes and
inhibiting survival of activated T cells (Wuest 2011).
◦ Pegylated interferon beta-1a (PEG-IFN) is the drug
obtained by PEGylation of IFN beta-1a (Avonex®) (i.e. joining
of a polyethylene glycol group (PEG) molecule to the IFN beta-
1a molecule). PEGylation has been applied to increase IFN
stability, solubility and half-life, and to reduce dosing frequency
(Hu 2012).
◦ Cladribine is a chemotherapeutic drug approved for
treatment of patients with hairy-cell leukaemia, a subtype of
chronic lymphoid leukaemia. Short courses of cladribine induce
prolonged lymphopenia by selectively interfering with DNA
synthesis and repair in T and B lymphocytes lasting months to
years (Leist 2011).
◦ Mitoxantrone is a cytotoxic drug that intercalates with
DNA and inhibits both DNA and RNA synthesis, thus reducing
the number of lymphocytes (Fox 2004).
• Used off-label.
◦ Azathioprine is a cytotoxic immunosuppressive drug
that acts as a prodrug for mercaptopurine, inhibiting an enzyme
required for DNA synthesis. Thus it most strongly affects
proliferating cells, such as T cells and B cells of the immune
system (Tiede 2003).
◦ Intravenous immunoglobulins may improve
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remyelination of demyelinated axons through mediation of
cytokines. However, their mechanism of action in MS remains
unclear (Stangel 1999).
◦ Rituximab is a monoclonal antibody to CD20
expressed on pre-B and mature B cells; it acts by depleting these
cells in the circulation and the CNS. Although MS was
traditionally considered a T cell-mediated disease, accumulating
evidence suggests that B cells may play a role (Lycke 2015;
Naismith 2010).
• Currently under marketing authorisation or investigation.
◦ Laquinimod may have an immunomodulatory effect
on the peripheral and central nervous systems. This drug
modulates the function of various myeloid antigen-presenting
cell populations, which thendownregulate pro-inflammatory T
cell responses. Furthermore, data indicate that laquinimod acts
directly on resident cells within the CNS to reduce
demyelination and axonal damage. However, exactly how the
drug works remains unknown (Varrin-Doyer 2014).
◦ Ocrelizumab is a recombinant monoclonal antibody
designed to selectively target CD20 B lymphocytes that are
implicated in the pathogenesis of MS. Like rituximab,
ocrelizumab depletes CD20 B cells, but it increases antibody-
dependent cell-mediated cytotoxicity effects and reduces
complement-dependent cytotoxicity effects compared with
rituximab (Kappos 2011).
Why it is important to do this review
Uncertainty
Many treatment options are available, and patients and their clini-
cians may choose to start with a drug of moderate efficacy and gen-
eral safety or with a drug of high efficacy and a complex safety pro-
file. Consequently, a comprehensive appreciation of the benefits
and risks of all treatment approaches is urgently needed (Scolding
2015; Wingerchuk 2014). Some evidence from individual studies
shows the effects of various DMDs. Interferons and glatiramer
acetate are indicated by the FDA and the EMA for treatment of
people who have experienced a first attack and are at high risk
of recurrent attacks. Other immunotherapies have been reported
to delay recurrent attacks, but their benefit in terms of disability
remains unclear, and various national guideline bodies have pro-
vided conflicting information about effects of these treatments and
their use as first-line or second-line therapy (see Description of the
condition). This uncertainty results from several factors, including
intermediate outcomes and short follow-up periods in the clinical
trials included in published systematic reviews. Immunotherapies
administered early in the disease can delay intermediate outcomes
(i.e. short-term relapses), but their effect on relapses poorly cor-
relates with prevention of disability (Frischer 2009; Kinkel 2012;
Scalfari 2013). Therefore an effect on disability cannot be claimed
solely on the basis of relapse prevention (EMA 2015a). Safety out-
comes have not been investigated extensively primarily because
most evidence has been derived from short-term randomised trials
that have low power to investigate rare adverse events.
Patients and their doctors must be given information about the
relative benefit and safety of the various treatment options if they
are to make informed decisions. Various DMDs have been shown
to have different benefit/acceptability profiles. Differences in ben-
efit are as important to consider as differences in safety. For ex-
ample, local injection site reactions and flu-like symptoms have
emerged as the main adverse effects of interferons beta, and car-
diotoxicity and acute leukaemia as major safety issues of concern
for mitoxantrone. An increasing body of non-randomised stud-
ies published in the scientific literature have reported on rare ad-
verse events and have provided accumulating evidence. Investiga-
tors have described fatal cases of progressive multi-focal leucoen-
cephalopathy (PML) in patients treated with natalizumab (EMA
2006), fingolimod (EMA 2011) and dimethyl fumarate (EMA
2014a). The few adverse events mentioned here are described in
the large body of data on known and supposed drug-related ad-
verse events provided in the literature. Researchers must identify,
systematically collect and synthesise this information to provide a
summary of existing scientific evidence that will assist healthcare
providers and patients in making treatment decisions.
Relevance
In July 2014, the Cochrane Multiple Sclerosis Group launched a
‘Priority Setting Survey’ and invited consumers and MS societies
to answer a questionnaire identifying priority research questions
considered to have the most relevant impact for all stakeholders.
The question - “Early onset of treatment may avoid disease pro-
gression?” - was one of the most frequently reported by patients
and family members. The question - “Does early treatment with
aggressive disease modifying drugs improve the prognosis for peo-
ple with MS?” - addresses one of the top 10 MS priorities re-
ported by the James Lind Alliance in collaboration with the UK
MS Society 2012. This study aims to answer these two questions
by comparing all DMDs with placebo and going a step farther; it
also plans to provide an assessment of the relative effects of each
drug compared with one other along with a ranking of treatments
according to benefit and safety. The significance of this project is
underlined by the fact that evaluation of disease modifying drugs
for people with a first clinical episode has been identified as a pri-
ority and is featured in the Cochrane Priority Review List 2015/
16.
Most published reviews have compared a single treatment versus
placebo and have made inferences about benefits and safety. This
information is unlikely to be useful in practice, as people with MS
have several treatment options. Network meta-analysis (NMA),
an extension of the traditional pairwise meta-analysis, collates in-
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formation from studies comparing different treatments to form a
‘network of interventions’, providing information about the rela-
tive effects of all interventions included in the network, even those
not directly compared in any trial. NMA can provide a hierarchy
of treatments ordered by efficacy and safety.
None of the existing comparative effectiveness reviews have specif-
ically targeted DMD in early treatment. As the number of patients
who choose to start treatment soon after diagnosis increases, it is
important for healthcare providers to know the relative benefit and
safety of the various treatment options in this particular setting.
Another important limitation of existing reviews is that all include
randomised controlled trials. Although this study design is theo-
retically associated with low risk of bias when treatment efficacy is
estimated, it has several shortcomings. First, randomised trials do
not provide patient follow-up for a long period; consequently, this
design is not appropriate when rare safety outcomes are of interest.
Second, randomised trials are typically undertaken in highly se-
lected conditions and do not represent real-world settings. Conse-
quently, the generalisability of findings is doubtful. For these rea-
sons, interest in including non-randomised studies in the decision-
making process is growing (Faria 2015), and innovative methods
have been developed for combining data obtained through differ-
ent study designs (Schmitz 2013; Verde 2015). Overall, we believe
that despite the wealth of information and the plethora of studies
and reviews on treatments for MS, uncertainty surrounds the rel-
ative ranking of DMDs when treatment starts early. In particular,
the issue of safety is less well studied, as evidence from non-ran-
domised studies that provide useful information on adverse events
has not been systematically considered.
We believe that having access to high-quality health information
is a relevant component of good decision making and helps people
take control of their health. Our certainty comes from the results
of our previous studies, in which people with MS and their family
members told us that they want access to high-quality information
about MS from sources they can trust (Colombo 2014).
Potential to change or influence clinical practice or
health policy
The review will provide critical information necessary in making
informed healthcare decisions for people with MS, their caring
neurologists and their family members who are looking for infor-
mation about evidence of treatment outcomes. Note that marked
variability in treatment decisions has been reported, likely as the
result of physician preference and opinion (Palace 2013).We hope
that the results of this review will be understandable and useful for
patients and clinicians who seek tomakemore informed treatment
choices. Note that DMDs for MS are expensive, and that their use
has significant economic implications for the healthcare system.
Moreover, these treatments are ‘aggressive’ and are often associated
with high risk of serious adverse events or side effects, which indi-
rectly further increases treatment costs. Identifying treatment that
offers a better benefit and safety profile, with particular attention
to safety, may help to reduce indirect costs.
We will ensure that review results will be understandable, relevant
and useful for people with MS, healthcare professionals, MS soci-
eties, policy makers, guidelines developers and existing and poten-
tial research funders. To this end, we will prepare lay summaries
that will be disseminated online. Results of this review will also
guide those who are entitled to make regulatory decisions and will
inform those who have the responsibility of planning a future re-
search agenda, such as funding of future studies in MS. We be-
lieve that having access to high-quality health information is an
important component of good decision making and helps people
take control of their health. Our certainty comes from the results
of studies previously undertaken by the Cochrane Multiple Scle-
rosis Group, wherein people with MS and their family members
told us that they want access to high-quality information about
MS provided by sources they can trust (Colombo 2014; Colombo
2016; Hill 2012; Synnot 2014).
O B J E C T I V E S
• To estimate the benefit and safety of all DMDs that have
been evaluated in all studies (randomised and non-randomised)
for early treatment. We will employ novel, high-quality methods
for systematic reviews and network meta-analysis in
collaboration with the Cochrane Multiple Interventions Group.
• To evaluate the quality of the evidence provided by existing
studies. We will consider the credibility of included studies and
other characteristics of the evidence base as we characterise
conclusions pertaining to high, low or very low quality of
evidence.
We will undertake this review in accordance with the methods
described by the template protocol published online and will use
this template as we prepare the review.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Wewill include RCTs and non-randomised studies (NRSs) (open-
label extension studies (OLEs), controlled clinical trials (CCTs),
concurrent and historical cohort studies (CHs) and population-
based registries). Inclusion of NRSs is supported by the need to
provide evidence of long-term benefit and safety outcomes that
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cannot be studied in short-term randomised trials. We will base
our inclusion criteria for NRSs on those reported in the Cochrane
Handbook for Systematic Reviews of Interventions (Reeves 2011).
Open-label extension studies follow on from RCTs. At the end of
the double-blindphase of theRCT, participants are invited to carry
on with, or convert to, the active treatment for an additional study
period, during which all participants know they are being treated
with the active drug and no participants receive placebo. Early-
treatment cohorts and delayed-treatment cohorts are compared.
Participants and outcome assessors are kept unaware of the initial
treatment allocation throughout the open-label phase of the study.
A study is classified as a CCT when study author(s) do not state
explicitly that the study was randomised. The classification CCT
is also applied to quasi-randomised studies when the method of
allocation is known but is not considered strictly random. Exam-
ples of quasi-random methods of assignment include alternation,
date of birth and medical record number.
A concurrent cohort study is a follow-up study that compares
outcomes between participants who have received an intervention
and those who have not. Participants are studied during the same
(concurrent) period, either prospectively or, more commonly, ret-
rospectively. The historical cohort study is a variation on the tra-
ditional cohort study wherein the outcome from a new interven-
tion is established for participants studied during one period and
is compared with outcomes of those who did not receive the inter-
vention during a previous period (i.e. participants are not studied
concurrently). Common sources of cohort studies in MS include
registries and large-scale clinical databases.
We will include RCTs and NRSs with follow-up of at least one
year.
We will exclude non-comparative studies (e.g. within-participant
comparisons).
Types of participants
We will consider for inclusion adults (18 years of age or older)
with a first clinical attack according to the McDonald criteria
(McDonald 2001; Polman 2005; Polman 2011) (i.e. one attack;
objective clinical evidence of two lesions or one attack; objective
clinical evidence of one lesion (clinically isolated syndrome)). We
will accept the definition of a first clinical attack as reported by the
authors of primary studies. We will include participants with optic
neuritis, isolated brainstem or cerebellar syndrome or spinal cord
or other clinical syndrome as a first attack, and we will include
monofocal or multi-focal first attacks.
Types of interventions
Alemtuzumab, azathioprine, cladribine, daclizumab, dimethyl fu-
marate, fingolimod, glatiramer acetate, immunoglobulins, inter-
feron beta-1b, subcutaneous interferon beta-1a, intramuscular in-
terferon beta-1a, laquinimod, mitoxantrone, natalizumab, ocre-
lizumab, pegylated interferon beta-1a, rituximab and terifluno-
mide as monotherapy compared with placebo or another active
agent. We will include regimens irrespective of their dose and will
assume that treatments are ’jointly randomiseable’ across trial par-
ticipants (Salanti 2012).
We will exclude combination treatments; trials in which a drug
regimen was compared with different regimens of the same drug
without another active agent or placebo as a control arm; all non-
pharmacological treatments; and interventions consisting of over-
the-counter drugs.
Types of outcome measures
Primary outcomes
Primary benefit outcomes
• Disability worsening defined as the proportion of
participants who experienced confirmed disability worsening at
24 or 36 months, or at the end of the study. Disability worsening
is defined as a sustained increase in Expanded Disability Status
Scale (EDSS) score by at least 1 point, or by 0.5 point if the
baseline EDSS was greater than or equal to 5.5 during a period
when the patient had no relapses. The EDSS score quantifies
disability on the basis of assessment of neurological function and
ability to walk. Scores range from 0 (no neurological
abnormality) to 10 (death from multiple sclerosis) (Kurtzke
1983).
• Relapses defined as the proportion of participants who
experienced new relapses over 12, 24 or 36 months, or at the end
of the study. A relapse is defined as newly developed or recently
worsened symptoms of neurological dysfunction that last for at
least 24 hoursand occur in the absence of fever or other acute
diseases and are separated in time from any previous episode by
more than 30 days. We will also accept a more stringent 48-hour
criterion. A relapse can resolve partially or completely
(McDonald 2001; Polman 2005).
Primary safety outcomes
• Proportion of participants with at least one serious adverse
event (SAE) during the study.
• Proportion of participants who withdrew from the study
because of adverse events (AEs).
Secondary outcomes
• Proportion of participants who discontinued treatment for
any reason during the study.
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Search methods for identification of studies
We will apply no language restrictions to the search.
Electronic searches
TheTrials SearchCo-ordinatorwill search theTrialsRegister of the
CochraneMultiple Sclerosis and Rare Diseases of theCNSGroup,
which, among other sources, includes trials from the following.
• Cochrane Central Register of Controlled Trials
(CENTRAL) (2016, most recent issue).
• MEDLINE (PubMed) (1966 to date).
• EMBASE (EMBASE.com) (1974 to date).
• Cumulative Index to Nursing and Allied Health Literature
(CINAHL) (EBSCOhost) (1981 to date).
• Latin American and Caribbean Health Science Information
Database (LILACS) (Bireme) (1982 to date).
• ClinicalTrials.gov (www.clinicaltrials.gov).
• World Health Organization (WHO) International Clinical
Trials Registry Platform (apps.who.int/trialsearch).
Information on the Trials Register or the ReviewGroup and details
of the search strategies used to identify trials can be found in
the ’Specialised Register’ section within the Cochrane Multiple
Sclerosis and Rare Diseases of the CNS Group module.
We have listed in Appendix 1 the keywords that we will use to
search for trials for this review.
We will perform an expanded search to identify articles on non-
randomised clinical trials in the following databases: MEDLINE
(Appendix 2) and EMBASE (Appendix 3).
Searching other resources
• We will handsearch the reference lists of all retrieved
articles, texts and other reviews on the topic.
• We will contact study authors and researchers active in this
field to ask for additional data, if necessary.
• We will search FDA and EMA reports on all of the
treatments included in this review.
Data collection and analysis
Selection of studies
We will use the search strategy described above to obtain titles and
abstracts of studies thatmay be relevant to the review. Two teams of
three review authors each (MC,MMand AS;OB, FP andGF) will
assess titles and abstracts to identify relevant studies for inclusion.
We will note studies and reviews that might include relevant data
and will obtain the full text of these studies when necessary to
confirm inclusion. We will include all completed RCTs, OLEs,
CCTs, CHs and registries meeting the inclusion criteria listed
above. We will link multiple publications of the same study as
companion reports, but we will exclude true duplicates. We will
resolve discrepancies in judgement by discussion between review
authors.
Data extraction and management
The three review authors on each team will independently extract
data using anExcel sheet thatwill be piloted on two articles. Review
authors will resolve disagreements on extractions by discussion.
Outcome data
We will extract from each included study the number of partici-
pants who:
• had relapses or worsening of disability at 12, 24 or 36
months, or at the end of the study;
• discontinued treatment for any reason during the study;
• withdrew because of any AE during the study; and
• had reported at least one SAE during the study.
We will extract arm-level data when possible and will extract effect
sizes when not possible. When timing of outcome measures was
not reported at selected time points, we will extract data as close
as possible to that time point. When the number of withdrawals
was not reported or was unclear in the primary study, we will rely
on reports from the FDA or EMA, or we will ask the trial author
to supply data.
Data on potential effect modifiers in RCTs
We will extract from each included RCT data on the following
potential effect modifiers.
• Participants: age, baseline MRI eligibility criteria,
monofocal or multi-focal first attack, proportion of participants
treated with steroids at the first attack.
• Outcomes: definitions of relapse and disability worsening.
• Interventions: dose, frequency or duration of treatment.
• Risk of bias for each outcome: allocation concealment,
blinding of participants and outcome assessors, incomplete
outcome data.
• Study years (realisation).
Data on potential confounders in NRSs
• Differences between treated and untreated individuals at
treatment start: age, disease duration, EDSS score, previous
treatments.
• Type of analysis done to account for confounding (e.g.
baseline confounding at the OLE phase, switch to other
treatment during the OLE phase).
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Assessment of risk of bias in included studies
RCTs
We will evaluate the risk of bias (RoB) of each included study us-
ing the tools of The Cochrane Collaboration for RCTs (Higgins
2011). These include random sequence generation, allocation con-
cealment, blinding of personnel, blinding of participants, blind-
ing of outcome assessors, incomplete outcome data, selective out-
come reporting, evidence of major baseline imbalance and role of
the sponsor. We will explicitly judge the RoB on each criterion
as ’low’, ’high’ or ’unclear’. We will judge complete outcome data
as having low RoB when numbers and causes of dropouts were
balanced (i.e. in the absence of a significant difference) between
arms. We will assess selective outcome reporting bias by compar-
ing outcomes intended to be analysed using the published study
protocol along with published study results. To summarise the
quality of the evidence, we will consider allocation concealment,
blinding of outcome assessors and incomplete outcome data to
classify each study as having low RoB when all three criteria are
judged as having low RoB; high RoB when at least one criterion is
judged as having high RoB; unclear RoB when all three criteria are
judged as having unclear RoB; and moderate RoB in remaining
cases. Allocation concealment and blinding of outcome assessor
are not expected to vary in importance across the two primary ben-
efit outcomes (disability worsening and relapses), but incomplete
outcome data might vary, and in that case we will summarise the
RoB of each RCT by considering the two outcomes separately.
We will assess RoB for AEs by considering specific factors that
may have a large influence on AE data. We will evaluate methods
of monitoring and detecting AEs in each primary study: Did re-
searchers actively monitor for AEs (low risk of bias), or did they
simply provide spontaneous reporting of AEs that arose (high risk
of bias)? Did study authors define AEs according to an accepted
international classification and report the number of SAEs? (Singh
2011) We will report RoB for AEs in an additional table called
’Assessment of adverse events monitoring’.
The first team (MC, MM and AS) will independently assess the
RoB of each RCT and will resolve disagreements by discussion to
reach consensus.
Non-randomised studies (NRSs)
We will evaluate the RoB of each included study using the
ROBINS-I tool for NRS (Sterne 2014) to provide the corre-
sponding RoB (i.e. low/moderate/serious/critical/no information
for each of the seven ROBINS-I domains including confound-
ing, selection of participants into the study, classification of inter-
ventions, departures from intended interventions, missing data,
measurement of outcomes and selection of reported results). We
will provide the overall RoB judgement on the basis of four key
domains: confounding, selection of participants, missing data and
measurement of outcomes (i.e. blinding of outcome assessors). We
will base the overall RoB judgement on the four key domains: low
RoB if the study is judged to be at low RoB for all four key do-
mains; moderate RoB if the study is judged to be at low or mod-
erate RoB for all four domains; serious RoB if the study is judged
to be at serious RoB for at least one of the four domains; critical if
the study is judged to be at critical RoB for at least one of the four
domains; and no information if no clear indication shows that the
study is at serious or critical RoB and information for one or more
of the four domains is lacking.
Other potential RoB, including that for AEs, is the same as in
RCTs. The second team of review authors (OB, FP and GF) will
independently assess RoB for each NRS and will resolve disagree-
ments by discussion to reach consensus.
Measures of treatment effect
We will estimate treatment effects from each study using risk ra-
tios (RRs) for binary data. We will also estimate hazard ratios or
cumulative probability at the end of follow-up on the basis of
Kaplan-Meier for each arm, or the crude probability (%) as the
number of people with disability worsening and the number of
randomised participants in each arm. We will estimate, through
pairwise meta-analysis, treatment effects of competing interven-
tions by using RRs with 95% confidence intervals (95% CIs) for
each outcome at each time point. We will present results from
network meta-analysis as summary relative effect sizes (RRs) for
each possible pair of treatments.
Unit of analysis issues
Cluster and cross-over trials have not been carried out to evaluate
DMDs for MS. We will perform separate analyses for participants
who had relapses at 12, 24 or 36 months, or at the end of the
study, and disability worsening at 24 or 36 months, or at the end
of the study.
For multi-arm trials, intervention groups will be all those that
can be included in a pairwise comparison of intervention groups,
which, if investigated alone, would meet the inclusion criteria.
For example, if a study compares ’interferon beta versus natal-
izumab versus interferon beta plus natalizumab’, only one com-
parison (’interferon beta vs natalizumab’) addresses the review ob-
jective, and no comparison involving combination therapy does
this. However, if the study compares ’interferon beta-1b versus
interferon beta-1a (Rebif ) versus interferon beta-1a (Avonex)’, all
three treatment groups are relevant to the review. In this case, we
will treat the multi-arm studies as multiple independent two-arm
studies in pairwise meta-analysis; we will account for the correla-
tion between effect sizes from multi-arm studies in the network
meta-analysis. We will convert multi-arm trials involving the same
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drug at different doses compared with a control treatment to a
single arm by merging doses and summing the number of events
and the sample size.
Dealing with missing data
To assess the effect of missing outcome data, we will analyse data
according to a likely scenario (i.e. we will assume that both treated
and control group participants who contributed to missing out-
come data had an unfavourable outcome (relapse or disability
worsening)).
Assessment of heterogeneity
To assess clinical heterogeneity within pairwise treatment compar-
isons, we will use data on potential effect modifiers in RCTs and
data on potential confounders in NRSs and will compare them
for each pair of interventions.
The transitivity assumption underlying NMA claims that treat-
ment effects for A versus B estimated directly (in A vs B stud-
ies) or indirectly (by combining A vs C and B vs C studies) are
in agreement. Transitivity holds when the distributions of poten-
tial effect modifiers are balanced across all pairwise comparisons
(Salanti 2012); in such cases, direct and indirect evidence can be
combined. We will compare the distribution of potential effect
modifiers across different pairwise comparisons to assess transitiv-
ity across treatment comparisons (Cipriani 2013). If transitivity
is deemed defendable, we will consider an NMA appropriate to
synthesise the data.
Assessment of reporting biases
We will evaluate the possibility of reporting bias by using a con-
tour-enhanced funnel plot for active interventions versus placebo.
The plot indicates areas of statistical significance and helps to dis-
tinguish reporting bias from other possible reasons for funnel plot
asymmetry (Chaimani 2013; Peters 2008).
Data synthesis
We will first perform standard pairwise meta-analyses using a ran-
dom-effects model for every treatment comparison with at least
two studies. Then, we will perform NMA in a frequentist context
by using a random-effects model. We will present the results of
NMA by using league tables and forest plots (Chaimani 2013).
To present trade-offs between benefit and safety, we will use two-
dimensional plots. For each active intervention, we will present
its average benefit for relapses and disability worsening versus its
safety.
We will conduct the pairwise meta-analysis in Review Manager
(RevMan 2016), and the NMA in STATA v13.
Subgroup analysis and investigation of heterogeneity
Wewill estimate different heterogeneity variances for each pairwise
comparison evaluated in standard pairwise meta-analyses, and we
will assess the presence of statistical heterogeneity by visually in-
specting the forest plots and by calculating the I2 statistic (Higgins
2003). InNMA,wewill assume a commonestimate for the hetero-
geneity variance across comparisons and will base the assessment
of statistical heterogeneity in the entire network on the magnitude
of the common heterogeneity parameter (Rhodes 2015; Turner
2012).
We will evaluate statistical disagreements between direct and indi-
rect effect sizes (inconsistency) by using the ‘design-by-treatment’
Q-statistic (Higgins 2012).We will conduct all analyses in STATA
v13 (White 2011). In the presence of moderate heterogeneity and/
or inconsistency, we will explore the impact of potential study
and patient-level co-variates using network meta-regression and
subgroup analysis. Potential sources of heterogeneity and incon-
sistency include baseline mean age, monofocal or multi-focal first
attack, definitions of relapse and disability worsening, dose, fre-
quency or duration of treatment, calendar year of study realisation
and risk of bias.
Sensitivity analysis
We do not anticipate performing a sensitivity analysis.
’Summary of findings’ table
We will present the main results of the review in a ’Summary of
findings’ (SoF) table. We will present a judgement about the cred-
ibility of evidence, inspired by the GRADE (Grades of Recom-
mendation, Assessment, Development and Evaluation Working
Group) method (Puhan 2014; Salanti 2014), for three patient-im-
portant outcomes: relapses, disability worsening and proportion
of participants with at least one SAE.We will transform risk ratios
to absolute treatment effects.
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A P P E N D I C E S
Appendix 1. Keywords
clinically isolated syndrome* OR first demyelinating event* OR first demyelinating episode OR first demyelinating attack OR
First event OR first episode OR first clinical episode OR single clinical episodes OR first demyelinating event* OR clinically
isolated syndrome*
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Appendix 2. MEDLINE
((((((((((((((((((((“clinically isolated syndrome*”[Title/Abstract]) OR cis“[Title/Abstract]) OR ”first demyelinating
event*“[Title/Abstract]) OR ”first demyelinating episode“[Title/Abstract]) OR ”first demyelinating attack“[Title/Abstract]) OR
First event[Title/Abstract]) OR ”first episode“[Title/Abstract] OR ”first clinical episode“[Title/Abstract] OR ”single clinical
episodes“[Title/Abstract])))))) OR first demyelinating event*[Text Word]) OR clinically isolated syndrome*[Text Word]))
AND
((((((((((((”Multiple Sclerosis“[Mesh:noexp]) OR (”Multiple Sclerosis/diagnosis“[Mesh:noexp] OR ”Multiple Sclerosis/ther-
apy“[Mesh:noexp]))) OR (”multiple sclerosis“[Title/Abstract]) OR ”optic neuritis“[Title/Abstract]) OR ”optic neuritis“[Title/
Abstract]))) OR ”early multiple sclerosis“[Title/Abstract]) OR ”early stage multiple sclerosis“[Title/Abstract] OR conversion
to multiple sclerosis[Title/Abstract]))) OR early stage multiple sclerosis[Text Word]) OR conversion to multiple sclerosis[Text
Word])
Appendix 3. EMBASE
#27 #13 AND #26
#26 #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25
#25 multiple AND sclerosis NEAR/5 treatment*
#24 conversion NEAR/5multiple AND sclerosis
#23 conversion NEXT/5 multiple AND sclerosis
#22 multiple AND sclerosis NEAR/5 early AND stage
#21 multiple AND sclerosis NEAR/5 early
#20 ’early stage multiple sclerosis’:ab,ti
#19 ’early multiple sclerosis’:ab,ti
#18 ’optic neuritis’:ab,ti
#17 optic AND ’neuritis’/exp
#16 ’multiple sclerosis’:ab,ti
#15 multiple AND ’sclerosis’/exp
#14 multiple AND ’sclerosis’/mj
#13 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12
#12 single AND clinical AND episode*:ab,ti
#11 ’single clinical episode’:ab,ti
#10 clinically AND isolated AND syndrome NEAR/5 first AND attack
#9 clinically AND isolated AND syndrome NEAR/5 first AND attack*
#8 clinically AND isolated AND syndrome NEAR/5 first AND episode
#7 clinically AND isolated AND syndrome NEAR/5 first AND event*
#6 first AND demylinating AND attack*:ab,ti
#5 first AND demylinating AND episode:ab,ti
#4 first AND demylinating AND event*:ab,ti
#3 clinically AND isolated AND syndrome* NEAR/5 cis
#2 ’clinically isolated syndromes’:ab,ti
#1 ’clinically isolated syndrome’:ab,ti
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